Clinical trial

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

NCT05361915

StatusSUSPENDED

Study typeINTERVENTIONAL

Start date2025-09-01

PhasePHASE2

Study timeline

Study start (estimated)2025-09-01Date precision: month

Registry last updated2024-03-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Prostate Cancer Metastaticunresolved

Interventions

AbivertinibDRUG

AbirateroneDRUG · verified · RxNorm: abiraterone

Sponsors & collaborators

Sorrento Therapeutics, Inc.lead sponsor

Mapped research locations

ClevelandOhio, United States1 La JollaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05361915 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.